CDC Vaccine Advisory Committee Convenes to Vote on Hepatitis B and COVID-19 Vaccines

Insights from the Second Day of the Advisory Committee Meeting

Day One: Measles and Hepatitis B Focus

On Thursday, the Advisory Committee on Immunization Practices concentrated its discussions on the hepatitis B vaccine and the combined measles, mumps, rubella, and varicella (MMRV) vaccines.

Decisions were made to alter guidelines for administering the MMRV vaccine. It was determined that children younger than 4 years should not receive the combined vaccine. The panel advised administering separate doses of the measles-mumps-rubella and the varicella vaccines, often referred to together as MMR+V, to this age group.

Deliberations related to the hepatitis B vaccine were concluded, but the final decision was postponed until Friday.

Contentious Discussions on Hepatitis B Vaccination

The Thursday session of the ACIP saw varying opinions regarding the hepatitis B vaccination policy for newborns. There were different interpretations of the data, which informed the discussion ahead of the voting.

Dr. Cody Meissner, a former member of the FDA’s vaccine committee and a pediatric expert, affirmed the vaccine's safety, stating that there is no evidence of risk.

He expressed concern that revising current recommendations could increase risks without a clear benefit, as fewer children might complete the full hepatitis B series.

Dr. Meissner highlighted the importance of initiating the vaccine within the first 12 to 24 hours after birth as a significant preventative measure.

In contrast, Vicky Pebsworth, a regional director with the National Association of Catholic Nurses, raised caution, citing remaining knowledge gaps regarding the vaccine’s impact on infants, suggesting that declaring it safe might be premature.

Implications of Hepatitis B Recommendation Changes

Dr. Adam Langer from the CDC presented information on the consequences of altering current hepatitis B vaccination recommendations, emphasizing potential risks to unvaccinated children. Currently, newborns are advised to receive the vaccine immediately after birth.

Even if mothers test negative for the virus, Dr. Langer outlined scenarios that put newborns at risk if left unvaccinated, noting that about half of hepatitis B virus carriers are unaware of their infection.

Changing the recommendation could slightly reduce the incidence of mild adverse effects from the birth dose, with severe reactions like anaphylaxis being exceptionally rare, occurring at a rate of just over one per million doses.

Hepatitis B Vaccine Currently Endorsed for Newborns

The committee is weighing the possibility of adjusting recommendations for the hepatitis B vaccine. At present, the CDC advises the initial dose for newborns within 24 hours post-birth. This universal approach addresses missed hepatitis B infections during pregnancy.

Healthcare professionals argue that a birth dose ensures safety for infants who might have been exposed to the virus unintentionally. This preemptive measure is crucial, given the reduction in infection rates since its implementation.

Suggestions for change include deferring the first vaccine dose by a month if the mother is confirmed negative, though early vaccination would remain an option for families.

Chronic hepatitis B infection can result in severe long-term health issues, such as liver cirrhosis and cancer.

New Appointees to the Advisory Committee by RFK Jr.

Following an overhaul of the committee, HHS Secretary Robert F. Kennedy Jr. appointed eight new members to the ACIP, with one later stepping down. Some appointees are allies with a history of critiquing vaccines.

Kennedy's appointments were made directly, marking a departure from previous practices where potential members were vetted by agency officials before receiving final approval.

These recent appointments include figures who have expressed skepticism towards mainstream vaccine research and policies concerning the COVID-19 pandemic.